ArticleQuantitative imaging in medicine and surgery2024
Added value of amide proton transfer-weighted magnetic resonance imaging to Prostate Imaging Reporting and Data System version 2.1 in differentiating clinically significant prostate cancer.
Article in Quantitative imaging in medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives.Abdominal radiology (New York) · 2026Review
- PI-RADS v2.1 for prostate MRI: current applications, ongoing debates, and synergies with advanced technologies-a narrative review.Translational andrology and urology · 2026Review
- Multiparametric magnetic resonance imaging (MRI) integrating amide proton transfer-weighted (APTw) imaging, synthetic MRI, and multiplexed sensitivity encoding diffusion-weighted imaging (MUSE DWI) in the diagnosis and grading of prostate cancer.Quantitative imaging in medicine and surgery · 2026Article
- Exploring the value of multiparametric quantitative magnetic resonance imaging in avoiding unnecessary biopsy in patients with PI-RADS 3-4.Abdominal radiology (New York) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) remains uncertain. This study aimed to investigate the added value of APTw-MRI and ADC to PI-RADS v. 2.1 in differentiating csPCa. Methods: This study included 161 participants who underwent prostate biopsy or radical prostatectomy within 1 month following MRI. Six magnetic resonance (MR) parameters [minimum APT value (APTmin), maximum APT value (APTmax), mean APT value (APTmean), minimum ADC value (ADCmin), maximum ADC value (ADCmax), and mean ADC value (ADCmean)] and the PI-RADS score were acquired by two radiologists. Receiver operating characteristic (ROC) curve analysis was performed to evaluate and select parameters with the greatest performance from the APT and ADC values. Multivariate logistic regression analysis was conducted to construct models based on selected MR parameters and the PI-RADS score. The Delong test was applied to compare the area under the ROC curve (AUC) between models. Results: The lesions of csPCa exhibited higher APT values and lower ADC values than not clinically significant prostate cancer (ncsPCa). The greatest comprehensive performance in differentiating csPCa was achieved by APTmean (AUC: 0.723; cutoff value: >1.644) and ADCmean (AUC: 0.759; cutoff value: <0.656). The addition of APTmean significantly improved the performance of the model based on the PI-RADS score (AUC: APT PI-RADS 0.867 Conclusions: APTw-MRI and ADC are valuable parameters for differentiating csPCa and can provide additional value for improving the efficiency and clinical benefit of PI-RADS v. 2.1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.